

# Medidata Corporate Overview

### Powering Smarter Treatments and Healthier People

Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes.

## Our Pioneering Solutions and Services

The **Medidata Platform** is the life science industry's only unified platform addressing the holistic clinical research process from start to finish, focused on **precision medicine**, **sustainable innovation**, and **patient centricity**. Medidata's focus on **evidence generation**, **clinical data management**, **clinical operations**, and **decentralized clinical trials (DCT)** is transforming the clinical trial experience for company **partners**, including patients, sponsors, CROs and research sites.

**Rave Data Management** streamlines data acquisition, aggregation, and review to enable data managers to deliver high-quality datasets and reach database lock faster.

**Rave Clinical Operations** drives efficiency, agility, and decentralization of study execution with integrated site, investigator, and sponsor workflows, embedded analytic insights, and real-time data availability.

**Medidata AI** combines unparalleled clinical trial data with a unified platform, advanced analytics, and deep human expertise to help uncover breakthrough insights.

**Patient Cloud** is a suite of powerful solutions that makes it simple and engaging for patients to participate in any clinical trial – so trials are easier, faster, and produce better results.



#### Helping Life Sciences companies deliver innovative therapies to patients faster.

Medidata's dedicated experts ensure customers realize the most value by advising the implementation, adoption, and support of clinical trial technologies. **Medidata Professional Services** is the only technology partner with the expertise to power success through a personalized approach from a trusted team. Navigate the evolving landscape of clinical trials and achieve optimal outcomes with our deep domain experience on the industry's leading platform.



## Highlights

Medidata has achieved remarkable milestones as a trusted partner to the life sciences industry, including:



2,200+ customers (biopharma sponsors, CRO partners, MedTech)





countries





655+ industry sponsored COVID-19 studies across all phases and stages



9 out of the top 10 CROs partner with Medidata



Medidata involved in 23.2% of company-initiated trial starts globally in 2023



Medidata technology supported 65% of novel drugs approved by FDA in 2023



13 of the top 15 medicines sold in 2022 relied on Medidata technology



19 out of the top 20 Pharma companies partner with Medidata

## Corporate Social Responsibility is integrated into the fabric of Medidata.

#### Access for All

Medidata's patient-centric focus includes a commitment to increasing diversity in clinical trials and maintaining a focus on rare diseases.

**Diversity, Equity and Inclusion** are embedded in our culture's DNA. It is our diversity, inclusiveness, and ability to foster equality with our culture and practices that fuels innovation, sparks our passion and commitment to patient health.

#### **STEM Education**

A focus on mentoring, coding and access to learning and career advice, along with working to bring student ideas to life with the Tech Entrepreneurship Incubator.

#### The Social Innovation Lab

Medidata's unique skills-based volunteering program that pairs employees with non-profit partners to work on priority projects.

### Locations/Contact

U.S.: New York, NY; Iselin, NJ; Boston, MA; Houston, TX; San Francisco, CA; Cincinnati, OH; Davis, CA; San Mateo, CA; Tokyo, Japan; Seoul, South Korea; Singapore; London, UK (Beijing, China and Shanghai China - Dassault Systernes offices)















Analysis conducted by Medidata's statisticians, using the industry's largest clinical trial data set

1 Analysis of difference in median build time ve matched studies not using professional services (p.(0.05)
2 Analysis of difference in median PPI to LPLY time for EDC + at least one additional productive. EUC only studies (p.(0.05)
3 Analysis of difference in median LPLY to DBL time for EDC + at least one additional productive. EUC only studies (p.(0.05)
3 Analysis of difference in median LPLY to DBL time for EDC + at least one additional product ve EDC only studies.